EXACT Sciences Co. (NASDAQ:EXAS) Expected to Announce Earnings of -$0.56 Per Share

Wall Street brokerages forecast that EXACT Sciences Co. (NASDAQ:EXAS) will report earnings of ($0.56) per share for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for EXACT Sciences’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.52). EXACT Sciences posted earnings of ($0.30) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 86.7%. The business is scheduled to announce its next quarterly earnings results on Wednesday, August 7th.

On average, analysts expect that EXACT Sciences will report full-year earnings of ($2.21) per share for the current year, with EPS estimates ranging from ($2.39) to ($2.06). For the next year, analysts expect that the business will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.54) to ($0.49). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for EXACT Sciences.

EXACT Sciences (NASDAQ:EXAS) last released its earnings results on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.01). The business had revenue of $162.00 million during the quarter, compared to the consensus estimate of $153.07 million. EXACT Sciences had a negative net margin of 41.58% and a negative return on equity of 28.83%. The business’s revenue was up 79.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.33) EPS.

Several research firms have recently weighed in on EXAS. Zacks Investment Research upgraded EXACT Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, April 23rd. BidaskClub upgraded EXACT Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 16th. Craig Hallum restated a “buy” rating and set a $115.00 price target (up from $95.00) on shares of EXACT Sciences in a report on Wednesday, May 1st. UBS Group upped their target price on EXACT Sciences from $115.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Finally, BTIG Research upped their target price on EXACT Sciences to $130.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $108.45.

In other EXACT Sciences news, insider Mark Stenhouse sold 11,192 shares of the business’s stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $92.54, for a total value of $1,035,707.68. Following the transaction, the insider now directly owns 25,500 shares of the company’s stock, valued at $2,359,770. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.20% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Allstate Corp lifted its stake in EXACT Sciences by 1.4% in the first quarter. Allstate Corp now owns 7,080 shares of the medical research company’s stock valued at $613,000 after buying an additional 97 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC. raised its position in shares of EXACT Sciences by 2.4% during the first quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 4,250 shares of the medical research company’s stock worth $368,000 after purchasing an additional 100 shares during the period. Gofen & Glossberg LLC IL raised its position in shares of EXACT Sciences by 1.8% during the first quarter. Gofen & Glossberg LLC IL now owns 8,375 shares of the medical research company’s stock worth $725,000 after purchasing an additional 150 shares during the period. First Hawaiian Bank raised its position in shares of EXACT Sciences by 160.0% during the first quarter. First Hawaiian Bank now owns 325 shares of the medical research company’s stock worth $28,000 after purchasing an additional 200 shares during the period. Finally, CWM LLC raised its position in shares of EXACT Sciences by 35.3% during the first quarter. CWM LLC now owns 831 shares of the medical research company’s stock worth $72,000 after purchasing an additional 217 shares during the period. 86.27% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:EXAS traded down $2.32 during midday trading on Tuesday, hitting $111.45. 1,436,300 shares of the stock were exchanged, compared to its average volume of 1,788,674. The firm has a market cap of $14.61 billion, a PE ratio of -81.95 and a beta of 1.68. The company has a debt-to-equity ratio of 1.02, a current ratio of 8.39 and a quick ratio of 8.13. The business’s 50-day simple moving average is $103.41. EXACT Sciences has a 12 month low of $47.78 and a 12 month high of $117.98.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Story: Price to Earnings Ratio (PE) Basics

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.